BioSpace News Archive

Acceleron Announces First Quarter 2021 REBLOZYL ® Net Sales - Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb -

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the close of U.S. financial markets on Thursday, May 6, 2021.

Enosi Life Sciences , a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today its appointment of Jeff Huitt as Chief Financial Officer and Thomas Becker as VP, Investor Relations.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2021.

- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model - - Preclinical findings support increase of PPi levels as a predictive marker of therapeutic benefit -

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted for poster presentations during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Abbisko Therapeutics (“Abbisko”) in companion diagnostics (CDx). The two companies will work together to develop a CDx assay for ABSK091 (formerly known as AZD4547) to advance clinical research and development of the drug.